ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 410

Early Growth Response-1 (EGR-1) Controls Synoviocyte Apoptosis, and Its Expression Is Regulated by the Direct Binding of Fibroblast Growth Factor-1 (FGF1) or Insulin-Like Growth Factor-1 (IGF1) to Integrin αvβ3

Shino Tanaka1, Jun Saegusa1, Seiji Kawano1, Yoshikazu Takada2, Shunichi Kumagai3 and Akio Morinobu1, 1Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Dermatology, University of California, Davis, School of Medicine, Sacramento, CA, 3The Center of Rheumatic Diseases, Shinko Hospital, Kobe, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Apoptosis, growth factors and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Growth factors such as fibroblast growth factor (FGF) and insulin-like growth factor (IGF) are of interest in the initiation and development of rheumatoid arthritis (RA) synovial hyperplasia, because of their potent mitogenic and angiogenic activities. The traditional understanding of FGF and IGF signaling has held that their binding to their respective receptor (i.e., the FGF receptor [FGFR] or the IGF receptor [IGFR]) is sufficient to initiate signaling. We recently demonstrated that FGF1 binds directly to integrin αvβ3, and that an integrin-binding-defective FGF1 mutant (FGFR50E) cannot induce cell proliferation, even though the mutant still binds FGFR; this is also true for IGF1. In both cases, a ternary complex, FGF1-FGFR-integrin αvβ3 or IGF1-IGFR-integrin αvβ3, was formed. However, the mechanism underlying the cross-talk between growth-factor-receptor signaling and integrin signaling is unknown. Here we investigated how the growth factor-integrin αvβ3 interaction is involved in growth-factor signaling in RA synoviocytes.

 Methods: Several mutations were introduced at the interface of FGF1 or IGF1 with integrin αvβ3, and integrin-binding-defective FGF1 and IGF1 mutants (FGFR50E and IGFR36E/R37E) were generated. RA synoviocytes were stimulated with FGF1 or FGFR50E, and comprehensive gene-expression profiling was performed by cDNA microarray. Intracellular signaling in synoviocytes treated with FGF1, FGFR50E, IGF1, and IGFR36E/R37Ewas evaluated by real-time PCR and Western blot analyses. Synoviocytes transfected with scramble siRNA or early growth response-1 (EGR-1)-specific siRNA were treated with various apoptotic stimuli, and cell viability was measured by the WST-8 assay.

Results: The integrin-binding-defective mutants (FGFR50E and IGFR36E/R37E) showed a markedly reduced ability to induce the cell proliferation of RA synoviocytes. The cDNA microarray analysis showed significantly reduced EGR-1 mRNA expression in the FGFR50E-treated synoviocytes. Furthermore, EGR-1 mRNA and protein were rapidly induced in RA synoviocytes in response to FGF1 or IGF1, but the EGR-1 expression was significantly impaired in FGFR50E– or IGFR36E/R37E-treated synoviocytes. In addition, the down-regulation of EGR-1 by siRNA inhibited the apoptosis of synoviocytes treated with H2O2 or doxorubicin.

 Conclusion: EGR-1 plays a pivotal role in synoviocyte apoptosis, and its expression is regulated by the direct binding of FGF1 or IGF1 to integrin αvβ3. This integrin-growth factor interaction may be a novel therapeutic target for RA.


Disclosure:

S. Tanaka,
None;

J. Saegusa,
None;

S. Kawano,
None;

Y. Takada,
None;

S. Kumagai,
None;

A. Morinobu,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-growth-response-1-egr-1-controls-synoviocyte-apoptosis-and-its-expression-is-regulated-by-the-direct-binding-of-fibroblast-growth-factor-1-fgf1-or-insulin-like-growth-factor-1-igf1-to-int/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology